Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 11/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 10/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 2/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6661647 | 0.91 | MAPK14 (0.44) | CYP17A1CYP1A2HSD11B1HTR3A | |
| SCHEMBL6845459 | 0.87 | DHODH (0.41) | CYP17A1CYP1A2HSD11B1DHODH | |
| SCHEMBL6840591 | 0.86 | CYP17A1 (0.52) | CYP17A1CYP1A2 | |
| SCHEMBL6844285 | 0.86 | CYP11B2 (0.42) | CYP17A1CYP1A2TNFHTR6 | |
| SCHEMBL6845971 | 0.86 | SETD7 (0.41) | CYP17A1CYP1A2HTR6HSD11B1DYRK1A | |
| SCHEMBL6844416 | 0.84 | CDC7 (0.41) | CYP17A1CYP1A2HTR3A | |
| SCHEMBL6657600 | 0.84 | CYP11B1 (0.43) | CYP17A1CYP1A2 | |
| SCHEMBL6661929 | 0.82 | MET (0.42) | CYP1A2 | |
| SCHEMBL6847479 | 0.82 | CYP17A1 (0.40) | CYP17A1CYP1A2HTR3A | |
| SCHEMBL6847772 | 0.78 | DYRK1A (0.47) | CYP17A1CYP1A2TNFHTR6HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040236110-A1 | Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors | BAYER PHARMACEUTICALS CORPORATION | 2004-11-25 | — | — | US | disclosed |
| EP-1432698-A2 | SUBSTITUTED 3-PYRIDYL INDOLES AND INDAZOLES AS C17,20 LYASE INHIBITORS | Bayer Pharmaceuticals Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003027094-A2 | SUBSTITUTED 3-PYRIDYL INDOLES AND INDAZOLES AS C17,20 LYASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040236110-A1 | Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors | CYP17A1, IDO1, CYP21A2 | CYP17A1 1/4885CYP1A2 32/4885TNF 4642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.